Login / Signup

Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis.

Daigoro TakahashiClaudius ConradYukihiro YokoyamaTsuyoshi IgamiJunpei YamaguchiShunsuke OnoeNobuyuki WatanabeOsamu MaedaMasahiko AndoTomoki Ebata
Published in: Journal of hepato-biliary-pancreatic sciences (2021)
Compared with adjuvant GEM monotherapy, adjuvant S-1 monotherapy may improve survival in node-positive perihilar cholangiocarcinoma patients.
Keyphrases
  • early stage
  • end stage renal disease
  • lymph node
  • ejection fraction
  • chronic kidney disease
  • combination therapy
  • open label
  • prognostic factors
  • peritoneal dialysis
  • clinical trial
  • squamous cell carcinoma
  • rectal cancer